Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF secondary prophylaxis with CapeOX in colorectal cancer
ChiCTR2100051884Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in colorectal cancer (CRC), sponsored by First Hospital of China Medical University. Primary endpoint: Incidence of grade 2-4 neutropenia during the treatment period. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100051884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051884.